NCT03771183View on ClinicalTrials.gov

Loreline Study: Characterization of Long Responders Under Eribuline

CompletedOBSERVATIONAL
Enrollment

97

Participants

Timeline

Start Date

August 23, 2019

Primary Completion Date

November 30, 2020

Study Completion Date

February 28, 2021

Conditions
Breast Cancer PatientsTherapy Related Tumor
Interventions
OTHER

Patients in long response during Halaven® treatment

Data collection

Trial Locations (5)

25030

CHRU Jean Minoz, Besançon

42270

Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez

54519

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

63011

Centre Jean Perrin, Clermont-Ferrand

67065

Centre Paul Strauss, Strasbourg

All Listed Sponsors
lead

Centre Jean Perrin

OTHER

NCT03771183 - Loreline Study: Characterization of Long Responders Under Eribuline | Biotech Hunter | Biotech Hunter